Considering 30-days investment horizon, Hospira Inc. is expected to generate 0.48 times more return on investment than Nektar. However, Hospira Inc. is 2.07 times less risky than Nektar. It trades about -0.26 of its potential returns per unit of risk. Nektar Therapeutics is currently generating about -0.17 per unit of risk. If you would invest 3,542 in Hospira Inc. on April 26, 2012 and sell it today you would lose (304.00) from holding Hospira Inc. or give up 8.58% of portfolio value over 30 days.
Diversification
Very weak diversification
Overlapping area represents amount of risk that can be diversified away by holding Hospira Inc. and Nektar Therapeutics in the same portfolio (assuming nothing else is changed)
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
